Cleerly ISCHEMIA vs AI-ECG Platform
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a comprehensive, non-invasive assessment of coronary artery disease based on CCTA imaging. This tool is ideal for detailed evaluation of coronary plaque characteristics, stenosis severity, and vessel-level ischemia likelihood to inform personalized diagnosis and treatment strategies. It provides a deeper anatomical and functional insight beyond standard cardiac tests.
View Cleerly ISCHEMIA →Choose AI-ECG Platform if…
Choose the AI-ECG Platform if your primary need is rapid and accurate AI-powered interpretation of 12-lead resting ECGs. This system is best suited for quickly identifying common cardiovascular conditions such as arrhythmias, myocardial ischemia, or infarction, providing immediate diagnostic support in various clinical settings. It offers a fast and reliable initial screening or diagnostic aid.
View AI-ECG Platform →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | AI-ECG Platform |
|---|---|---|
| Pricing | Contact for details | Contact for pricing |
| Deployment | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) | Workstation (with GPU), web-based portal, Windows-based diagnostic client |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIACleerly ISCHEMIA (Tool A) emphasizes comprehensive interactive web-based reports and direct integration with existing radiology workflows via PowerScribe API, suggesting a streamlined and intuitive user experience for physicians. While Tool B offers multiple deployment options, Tool A's focus on seamless integration into established clinical workflows provides a stronger usability advantage.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA (Tool A) offers a more advanced and comprehensive clinical assessment by analyzing CCTA scans for non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood, and detailed coronary plaque characterization. This provides deeper insights for personalized diagnosis and treatment planning compared to the AI-ECG Platform's (Tool B) high-accuracy interpretation of 12-lead resting ECGs, which is valuable but less detailed in its scope.
Pricing & Value
TieBoth Cleerly ISCHEMIA (Tool A) and the AI-ECG Platform (Tool B) require direct contact for pricing details, indicating a lack of transparency. Without specific pricing information for either product, it is impossible to conduct a meaningful head-to-head comparison on their value proposition.
Enterprise Readiness
Cleerly ISCHEMIACleerly ISCHEMIA (Tool A) explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical for enterprise adoption in healthcare. Its web-based platform with secure data transfer via Cleerly Proxy and integration with PowerScribe via API also demonstrates readiness for integration into existing clinical IT environments. While Tool B supports various ECG data formats, its HIPAA and BAA status are not explicitly confirmed, which is a significant drawback for enterprise deployment.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA (Tool A) demonstrates greater innovation by leveraging AI to perform non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA scans. This represents a significant advancement in personalized cardiovascular risk assessment and moves beyond traditional diagnostic methods to provide deeper insights into disease pathology. The AI-ECG Platform (Tool B), while offering rapid and accurate ECG analysis, primarily enhances an existing diagnostic modality rather than introducing a fundamentally new approach to disease characterization.
Support & Docs
TieNeither the structured facts nor readily available web searches provide sufficient specific information regarding the depth of documentation, training programs, or dedicated support channels for either Cleerly ISCHEMIA (Tool A) or the AI-ECG Platform (Tool B). Both companies generally mention support, but a detailed comparison is not possible.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | AI-ECG Platform |
|---|---|---|
| Name | Cleerly ISCHEMIA | AI-ECG Platform |
| Company | Cleerly | Shenzhen Carewell Electronics Co., Ltd. |
| Primary Function | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | AI automatic analysis and diagnosis system for ECG, designed to assist physicians in interpreting 12-lead resting ECGs with high accuracy. |
| Primary Data Input | CCTA scans | 12-lead resting ECGs |
| Key Analysis Output | Non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, coronary plaque characterization (volume, type, location), stenosis severity assessment, 3D digital models of coronary arteries, comprehensive interactive web-based reports. | AI-powered automatic ECG analysis and diagnosis, diagnoses arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction, rapid diagnosis in approximately 3 seconds, professional ECG review, waveform measurement, and report generation. |
| Specialties | Cardiology, Radiology | Cardiology, Emergency Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and AI-ECG Platform.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or AI-ECG Platform
Backers
Who funded each tool's parent company.